News

Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections

First-in-human study for ETH47 to evaluate safety, tolerability, and target engagement in healthy participantsMUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE)…

2 years ago

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration

RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaboration RoslinCT will manufacture world’s-first CRISPR-based…

2 years ago

Crossject announces initiation of coverage by ODDO BHF

Rated “Outperform” with price target of €7.10 Analysts cite $60 million BARDA contract for Crossject’s ZEPIZURE® as validation of platform…

2 years ago

Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023

Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 Halle (Saale) / Munich,…

2 years ago

Tinley’s Files Interim Results and Announces Investor Call

Toronto, Ontario and Los Angeles, California--(Newsfile Corp. - November 28, 2023) - The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB:…

2 years ago

Delivra Health Brands and its Leading Brands Dream Water (R) and LivRelief (TM) Report Positive Adjusted EBITDA(1) for First Quarter of Fiscal 2024

Vancouver, British Columbia--(Newsfile Corp. - November 28, 2023) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or…

2 years ago

FendX Technologies to Present at the SHARE(TM) Series Monday Management Update on December 4, 2023

Oakville, Ontario--(Newsfile Corp. - November 28, 2023) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or…

2 years ago

AlzeCure Presents at DNB Nordic-American Healthcare Conference in New York December 6-7

STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…

2 years ago

Interim Report, January-September 2023

STOCKHOLM, SWEDEN / ACCESSWIRE / November 28, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0)July to SeptemberNet sales amounted to MSEK 0 (0)Net…

2 years ago

Renegade.health Announces the PrEPforBetter Campaign Now Available Nationwide

Renegade.health At-Home PrEP/STI Collection Kit discreetly and effectively helps underserved communities to get on PrEP.SAN FRANCISCO, CA / ACCESSWIRE /…

2 years ago